This study evaluates the impact of the agonal phase and related hemodynamic measures on post-transplant outcomes and heart utilization in donation after circulatory death (DCD) heart transplantation. United Network for Organ Sharing registry was queried to analyze adult recipients who underwent isolated DCD heart transplantation between January 1, 2019 and September 30, 2023. The recipients were stratified into 2 groups based on donor agonal period: <30 and ≥30 minutes. The primary outcome was 90-day post-transplant survival. Propensity score-matching was performed. Sub-analysis was performed to evaluate the association of agonal period with donor heart utilization. Additionally, the associations between different hemodynamic thresholds used to indicate onset of warm ischemia during the agonal phase with 90-day mortality were compared. Eight hundred and eighty nine recipients were included, with 179 (20.1%) receiving hearts from donors with an agonal period of ≥30 minutes. Ninety-day survival (88.1% vs. 95.6%, p < 0.001) was significantly lower among the recipients of donors with an agonal period of ≥30 minutes. The lower 90-day survival persisted in a propensity score-matched comparison. Furthermore, longer agonal periods were associated with reduced donor heart utilization. Lastly, a time interval from a systolic blood pressure of 80 ± 5mmHg to death exhibited significantly higher association with 90-day mortality than a time interval from a systemic oxygen saturation 80 ± 5% to death. Utilizing DCD donor hearts with agonal periods ≥30 minutes is associated with reduced post-transplant survival and decreased donor heart utilization. When assessing the onset of warm ischemia during the agonal phase, hypotension may serve as a more accurate indicator of myocardial ischemia and provide improved post-transplant prognostic insight than hypoxia.
Heart transplantation remains the preferred treatment for carefully selected patients with end-stage heart failure refractory to medical therapy. Advances in donor management, organ preservation, donor and recipient selection, immunosuppressive strategies, and mechanical circulatory support have significantly improved the safety and efficacy of heart transplantation. However, the persistent shortage of donor hearts and their limited preservation period continues to restrict access to this lifesaving procedure. The advent of innovative machine perfusion and temperature control systems for heart allograft preservation offers a promising avenue to address these challenges. These technologies aim to extend preservation times and enable the use of extended-criteria donors, thereby expanding the donor pool. In this review, we examine the outcomes from clinical trials, registry data, and single-center studies, utilizing the TransMedics Organ Care System Heart, Paragonix SherpaPak Cardiac Transport System, and XVIVO Heart Preservation System. As the field of heart transplantation evolves to accommodate longer ischemia times, expand organ sharing, and utilize donors previously considered marginal, the integration of these advanced technologies will be essential for optimizing post-transplant outcomes.